Dialysis centers, the gatekeepers of kidney transplantation waitlisting, produce more data and inspire more policies today than ever before. However, existing Dialysis Facility Compare (DFC) quality metrics for these centers have not included longitudinal metrics, such as time to transplantation…
Read More
Excluding race factor from kidney function estimates may affect clinical outcomes for Black cancer patients
Removing race as a factor in a kidney function-estimating equation used to guide cancer treatment dosing and eligibility may decrease the proportion of Black patients recommended to receive full doses of anticancer drugs, according to an analysis of 15 years…
Read More
Study estimates duration of employment loss experienced by adults with kidney failure
A new study estimates the years of employment loss experienced by working-aged adults with kidney failure. The study, which will appear in an upcoming issue of CJASN, notes that most of this lost time is due to patients’ loss of…
Read More
People with intellectual disability more likely to die from COVID-19 than general population
Intellectual disability puts individuals at higher risk of dying earlier in life than the general population, for a variety of medical and institutional reasons. A new study from Jefferson Health examined how the COVID-19 pandemic has affected this group, which…
Read More
New web-based tool predicts the risk of post-surgical complications
Heart attack, kidney failure, stroke. These are just a few of the life-threatening complications that patients are at risk for following surgery. Now Jefferson researchers have developed an easy-to-use, web-based tool that predicts the risk of post-surgical complications such as…
Read More
Waitlist policies may contribute to racial disparities in kidney transplant access
Despite efforts to address them, racial disparities in access to kidney transplantation persist in the United States. New research published in an upcoming issue of JASN indicates that policy changes surrounding patients’ eligibility to be put on kidney transplant waitlists…
Read More
New blood pressure-lowering guidelines could benefit 25 million Americans with chronic kidney disease
A recommendation for more intensive blood pressure management from an influential global nonprofit that publishes clinical practice guidelines in kidney disease could, if followed, benefit nearly 25 million Americans, according to an analysis led by researchers at the Johns Hopkins…
Read More
Cabozantinib most effective treatment for metastatic papillary kidney cancer
In a SWOG Cancer Research Network trial that put three targeted drugs to the test, the small molecule inhibitor cabozantinib was found most effective in treating patients with metastatic papillary kidney cancer—findings expected to change medical practice. These findings will…
Read More
Zocor (MK)
NOTICE: This Consumer Medicine Information (CMI) is intended for persons living in Australia. ZOCOR® Simvastatin Consumer Medicine Information What is in this leaflet This leaflet answers some common questions about ZOCOR.It does not contain all the available information. It does…
Read More
Amlodipine/Valsartan/HCT Novartis
NOTICE: This Consumer Medicine Information (CMI) is intended for persons living in Australia. VALSARTAN/AMLODIPINE/HCT NOVARTIS® 5/160/12.5, 5/160/25, 10/160/12.5, 10/160/25, 10/320/25 amlodipine besilate/valsartan/hydrochlorothiazide Consumer Medicine Information What is in this leaflet This leaflet answers some common questions about AMLODIPINE/VALSARTAN/HCT NOVARTIS. It…
Read More